CPC C07K 16/24 (2013.01) [A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01)] | 2 Claims |
1. An isolated bispecific antibody comprising a first antigen-binding site that binds to a first epitope on human CCL2 and a second antigen-binding site that binds a second epitope on human CCL2,
wherein
A) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:71;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:90;
and a VL domain comprising the amino acid sequence of SEQ ID NO:93;
or
B) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:71;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:91;
and a VL domain comprising the amino acid sequence of SEQ ID NO:93;
or
C) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:71;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:90;
and a VL domain comprising the amino acid sequence of SEQ ID NO:94;
or
D) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:72;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:90;
and a VL domain comprising the amino acid sequence of SEQ ID NO:94;
or
E) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:73;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:90;
and a VL domain comprising the amino acid sequence of SEQ ID NO:93;
or
F) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:73;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:90;
and a VL domain comprising the amino acid sequence of SEQ ID NO:94;
or
G) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:73;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:92;
and a VL domain comprising the amino acid sequence of SEQ ID NO:93;
or
H) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:73;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:91;
and a VL domain comprising the amino acid sequence of SEQ ID NO:93;
or
I) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:72;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:90;
and a VL domain comprising the amino acid sequence of SEQ ID NO:93;
or
J) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:72;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:92;
and a VL domain comprising the amino acid sequence of SEQ ID NO:93;
or
K) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:72;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:91;
and a VL domain comprising the amino acid sequence of SEQ ID NO:93;
or
L) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:74;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:90;
and a VL domain comprising the amino acid sequence of SEQ ID NO:93;
or
M) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:74;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:90;
and a VL domain comprising the amino acid sequence of SEQ ID NO:94;
or
N) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:74;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:92;
and a VL domain comprising the amino acid sequence of SEQ ID NO:93;
or
O) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:74;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:91;
and a VL domain comprising the amino acid sequence of SEQ ID NO:93;
or
P) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:71;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:92;
and a VL domain comprising the amino acid sequence of SEQ ID NO:93.
|